Skip to main content
OpenTrials
Completed

NCT Number: NCT06046001

AirWaze - Easy and Advanced Tools for CBCT Guided Lung Interventions

The goal of this clinical trial is to assess the overall usability of the Philips

AirWaze investigational device in patients indicated for CBCT-guided navigation bronchoscopy procedure. The main questions it aims to answer are to assess the:

* overall usability of the device * accuracy of the tool-in-lesion confirmation scan

Participants will undergo bronchoscopy with the new navigation device and additional confirmation scans. Follow-up visit at 7days will be performed.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Radboudumc

Nijmegen, Gelderland, Netherlands

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 years or older at the time of informed consent.
  • ASA physical status between 1 and 3.
  • Subject is willing and able to give written informed consent for clinical investigation participation prior to the procedure.
  • Subject has a pulmonary lesion with an indication for diagnostic evaluation following current clinical guidelines and/or as decided by multi-disciplinary team consultation.
  • Suitable for CBCT-guided endobronchial nodule biopsy under general anaesthesia.
  • Pre-procedural (PET-)CT scan is available prior to the CBCT-NB intervention.

Exclusion criteria

  • Aged 17 or younger at the time of informed consent.
  • ASA physical status is equal to and greater than 4.
  • Not willing or not able to give informed consent.
  • Does not indicate diagnostic evaluation with navigation bronchoscopy.
  • Not suitable for CBCT-guided endobronchial nodule biopsy via navigation bronchoscopy under general anaesthesia.
  • There is no recent pre-procedural (PET-)CT scan available.
  • Known bleeding disorders.
  • Contra-indication for temporary interruption of the use of anticoagulant therapy, such as acenocoumarol, warfarin, therapeutic dose of low molecular weight heparins, clopidogrel, or analogues, NOACs).
  • Known allergy for lidocaine or other allergies interfering with the procedure.
  • Uncontrolled pulmonary hypertension.
  • Recent and/or uncontrolled cardiac disease.
  • Compromised upper airway (e.g. concomitant head and neck cancer or central airway stenosis for any reason such that endobronchial access is considered unsafe).
  • Potentially confounding drug or device trial during the clinical study. Co-enrollment in concurrent trials may be allowed provided pre-approval is obtained from the Philips Clinical Study Manager.
  • All vulnerable subjects, such as immune-compromised subjects, subjects lacking the capacity to provide consent, patients in emergencies, pregnant or breastfeeding women, or any other subject who meets exclusion criteria, according to applicable national laws, if any.
  • Woman of childbearing potential who is known to be pregnant on admission.
  • Any condition that in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the subject in the study.
  • Subject is Philips employee or their family members residing with this Philips employee.

Treatment and study plan

AirWaze

Device

AirWaze - easy and advanced tools for CBCT guided lung interventions

Primary outcomes

  1. System Usability Scale (SUS)

    Time frame: after procedure, up to 2 hours

    System Usability Scale (SUS) of AirWaze investigational device. An average SUS of greater than 70 will indicate a good usability design of the AirWaze Software solution. The SUS will be measured per operator every 4 procedures. The questionnaire consists of a 10-item questionnaire with five response options for respondents; from Strongly agree to Strongly disagree. Minimum total score is 0 and maximum, 100.

  2. Number of Participants With Accurate Tool-in-lesion Confirmation Scan (Ultra-low Dose CBCT Scan) Compared to the Conventional Tool-in-lesion Confirmation Scan (CBCT Scan)

    Time frame: after procedure, up to 1 hour

    Accuracy of the tool-in-lesion confirmation scan (ultra-low dose CBCT scan) is defined as the number of participants where ultra-low dose CBCT scans were adequate to define tool-in-lesion compared to conventional CBCT scans (gold-standard). The accuracy is defined as the sum of the number of tool-in-lesion scans in both the ultra-low dose CBCT and conventional CBCT scans (i.e. true positives), and the number of no tool-in-lesion confirmation in both the ultra-low dose CBCT and conventional CBCT scans (i.e. true negatives), divided by the total number of ultra-low dose CBCT and conventional CBCT scan pairs.

    Image based tool-in-lesion confirmation accuracy of 90% will indicate that the ultra-low dose CBCT scan is postulated to be sufficient for navigation bronchoscopy.

Sponsors and collaborators

Lead sponsor

Philips Clinical & Medical Affairs Global

Industry

Registry information

Important dates

Study start
2023
Primary completion
2024
Study completion
2025
First posted
Sep 21, 2023
Registry last updated
Apr 16, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.